Enzymatically hydrolyzed Tremella fuciformis extract,
does it really help with Improvement of age-related cognitive function?
research showsAn eight-week double-blind RCT in 75 adults reported improvements in subjective memory complaints and selected cognitive tests, but allocation was uneven, with 15 participants on placebo and 60 on active treatment. It was one trial in the lineage of a Pulmuone-developed ingredient, without independent replication. The paper title alone cannot establish process identity with the recognized enzymatically hydrolyzed ingredient, resulting in C.
ads claimAdvertising may extend the claim to memory, concentration, and dementia prevention, while the direct evidence concerns eight-week cognitive-test outcomes in adults with subjective cognitive impairment.
Useful facts when choosing a product
- Research doses were 600 mg/day and 1200 mg/day.
- The trial lasted eight weeks and included only 15 participants in the placebo group.
- The recognized daily intake matches the trial doses, but the public paper does not fully establish identity of the enzyme-treatment process.
- Short-term adverse-event frequency was similar in active and placebo groups.
What the research actually shows
Ban 2018 randomized 75 adults with subjective cognitive impairment to 600 mg/day in 30 participants, 1,200 mg/day in 30, or placebo in 15 for eight weeks. Subjective memory complaints and selected short-term-memory and executive-function tests improved, but allocation was uneven at 15 placebo versus 60 active participants. The test material belongs to the lineage of a Pulmuone-developed ingredient, and no independent replication was identified. Similar wording and dose in the paper do not establish that its processing was identical to the recognized enzymatically hydrolyzed ingredient.
Why this is classified as C (52)
The direct RCT supports subjective and objective cognitive signals. Uneven allocation of 15 placebo versus 60 active participants, one short trial, a Pulmuone-developed ingredient lineage, unconfirmed process identity, and no independent replication result in C with 52 points.
Counterpoint. A short-term cognitive-improvement signal remains in people with subjective cognitive impairment, but it is not evidence of clinically meaningful anti-aging or dementia prevention.
Rejudgment record. Reassessment (cross-check reflected) — A positive eight-week RCT in 75 participants had 15 placebo versus 60 active participants, involved a Pulmuone-developed ingredient lineage, lacked independent replication, and cannot establish processing identity with the recognized enzymatically hydrolyzed ingredient from the paper title alone
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Ban S et al. 2018 | Eight-week randomized double-blind placebo-controlled trial | 15 | Not identified in the public abstract | Subjective memory complaint questionnaire as the primary endpoint, short-term memory, executive function, and brain gray matter | Active groups improved versus placebo in subjective memory complaints and selected short-term-memory and executive-function measures. | Key, single RCT; public documentation of enzyme-process identity is incomplete |
| Kang P et al. 2026 | Review of the regulatory system and individually recognized ingredients | Korean government research support | Classification of Korean individually recognized cognitive ingredients | Listed enzyme-treated Tremella fuciformis extract as an individually recognized cognitive-function ingredient. | Supportive for product identity |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-11).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-11 · Corrections: none
Cite this verdict
[Chamgap] Enzymatically hydrolyzed Tremella fuciformis extract x improvement of age-related cognitive function — Evidence Grade C·52. 2 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/cognition/enzyme-treated-tremella-age-related-cognition/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.